Spesolimab Efficacy and Safety in Patients with Moderate-to-Severe Palmoplantar Pustulosis: A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase IIb, Dose-Finding Study
ConclusionThe primary objective to demonstrate a non-flat dose –response relationship and proof-of-concept was not achieved; improvements with spesolimab occurred in secondary endpoints and in non-Asian patients, indicating potential modest benefits. Spesolimab was generally well tolerated (ClinicalTrials.gov NCT04015518). (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - September 20, 2023 Category: Dermatology Source Type: research
Responsiveness and Minimal Clinically Important Difference of the Infants and Toddlers Dermatology Quality of Life Questionnaire
ConclusionsResponsiveness for all age-specific versions of the InToDermQoL questionnaire was confirmed. MCIDs for the InToDermQoL are proposed as follows: 3-point change of the total score for age version 0 –11 months and 5-point for the age versions 1–2 years and 3–4 years. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - September 20, 2023 Category: Dermatology Source Type: research
Prevalence of Musculoskeletal Symptoms in Patients with Psoriasis and Predictors Associated with the Development of Psoriatic Arthritis: Retrospective Analysis of a US Claims Database
ConclusionIncreased prevalence rates of MSK symptoms and burden are experienced by patients newly diagnosed with PsO through 60 months of follow-up. Several baseline factors were associated with increased risk of PsA diagnosis. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - September 19, 2023 Category: Dermatology Source Type: research
Real-Life Effectiveness and Tolerance of Baricitinib for the Treatment of Severe Alopecia Areata with 1-Year Follow-Up Data
ConclusionBaricitinib is effective in treating patients with alopecia areata, particularly for the patchy phenotype, but with a risk of relapse after discontinuation. Safety data are reassuring, with lipid changes being the most frequent adverse event. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - September 17, 2023 Category: Dermatology Source Type: research
Efficacy of Guselkumab in Treating Nails, Scalp, Hands, and Feet in Patients with Psoriasis and Self-reported Psoriatic Arthritis
ConclusionsGuselkumab-treated patients with psoriasis and self-reported PsA showed meaningful improvements in nail, scalp, and palmoplantar psoriasis.Trial RegistrationVOYAGE-1 (ClinicalTrials.gov Identifier: NCT02207231) and VOYAGE-2 (ClinicalTrials.gov Identifier: NCT02207244). (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - September 15, 2023 Category: Dermatology Source Type: research
Hair Loss Profiles and Ritlecitinib Efficacy in Patients with Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study
ConclusionDistinct and clinically relevant hair loss profiles were identified in ALLEGRO-2b/3 participants. Ritlecitinib was efficacious compared with placebo, independent of hair loss profile at baseline.Trial registrationClinicalTrials.gov identifier, NCT03732807.Graphical abstract (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - September 14, 2023 Category: Dermatology Source Type: research
The IMPACT of the COVID-19 Pandemic on Prescription Drug Use in Patients with Psoriasis Vulgaris in Germany
ConclusionThroughout the COVID-19 pandemic the PSO indicated medication sales increased for first-line biological and second-line treatment. This shows that despite the pandemic impact, there continues to be an increase in sales volume for biologics. Only German federal states with intermittently very high COVID-19 incidences show a stagnation in sales volume. The reasons for this need to be investigated in further studies to possibly gain a better understanding of the concerns and uncertainties of patients with PSO. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - September 14, 2023 Category: Dermatology Source Type: research
Dermatology Life Quality Index in Thai Patients with Facial Port-Wine Stains
ConclusionThis study demonstrates that facial PWS reduces the QoL as measured by DLQI. We discovered that the QoL of patients and parents with PWS was significantly impaired. The main influencing factors were older age, the improved perception between gender, and PDL treatments. In addition, we found only five questions that are reliable for PWS. The adjusted five-item DLQI questionnaires are more appropriate regarding validity and reliability.Trial Registration NumberTCTR20230210001, COA no. si 1059/2020. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - September 14, 2023 Category: Dermatology Source Type: research
Increasing Access to Effective Systemic Treatments in Patients with Moderate-to-Severe Psoriasis: Narrative Review
AbstractPsoriasis is a chronic, immune-mediated inflammatory disease with a worldwide prevalence ranging between 0.51 and 11.43%. It results in a large clinical and social burden, with patients frequently suffering from reduced quality of life, psychologic distress and debilitating comorbidities. Biologic agents are used to establish and maintain disease control in patients with moderate-to-severe psoriasis and are essential to improving quality of life. However, a substantial proportion of patients have limited access to therapy due to economics, health policies and clinical considerations, which creates clinical unmet ne...
Source: Dermatology and Therapy - September 14, 2023 Category: Dermatology Source Type: research
Hair Loss Profiles and Ritlecitinib Efficacy in Patients with Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study
ConclusionDistinct and clinically relevant hair loss profiles were identified in ALLEGRO-2b/3 participants. Ritlecitinib was efficacious compared with placebo, independent of hair loss profile at baseline.Trial registrationClinicalTrials.gov identifier, NCT03732807.Graphical abstract (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - September 14, 2023 Category: Dermatology Source Type: research
The IMPACT of the COVID-19 Pandemic on Prescription Drug Use in Patients with Psoriasis Vulgaris in Germany
ConclusionThroughout the COVID-19 pandemic the PSO indicated medication sales increased for first-line biological and second-line treatment. This shows that despite the pandemic impact, there continues to be an increase in sales volume for biologics. Only German federal states with intermittently very high COVID-19 incidences show a stagnation in sales volume. The reasons for this need to be investigated in further studies to possibly gain a better understanding of the concerns and uncertainties of patients with PSO. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - September 14, 2023 Category: Dermatology Source Type: research
Dermatology Life Quality Index in Thai Patients with Facial Port-Wine Stains
ConclusionThis study demonstrates that facial PWS reduces the QoL as measured by DLQI. We discovered that the QoL of patients and parents with PWS was significantly impaired. The main influencing factors were older age, the improved perception between gender, and PDL treatments. In addition, we found only five questions that are reliable for PWS. The adjusted five-item DLQI questionnaires are more appropriate regarding validity and reliability.Trial Registration NumberTCTR20230210001, COA no. si 1059/2020. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - September 14, 2023 Category: Dermatology Source Type: research
